Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
Phase 1
Completed
- Conditions
- Alzheimers Disease
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2008-05-13
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 30
- Registration Number
- NCT00448799
- Locations
- 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
Phase 1
Completed
- Conditions
- Alzheimers Disease
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 30
- Registration Number
- NCT00439010
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 27
- Registration Number
- NCT00397228
- Locations
- 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Phase 2
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-01-21
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 3
- Registration Number
- NCT00200447
© Copyright 2025. All Rights Reserved by MedPath